SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-005228
Filing Date
2017-05-15
Accepted
2017-05-15 16:11:56
Documents
74
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0317_dandritbiotech.htm 10-Q 493186
2 CERTIFICATION f10q0317ex31i_dandritbio.htm EX-31.1 12162
3 CERTIFICATION f10q0317ex31ii_dandritbio.htm EX-31.2 11366
4 CERTIFICATION f10q0317ex32i_dandritbio.htm EX-32.1 5939
5 CERTIFICATION f10q0317ex32ii_dandritbio.htm EX-32.2 5970
  Complete submission text file 0001213900-17-005228.txt   3808601

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE ddrt-20170331.xml EX-101.INS 590736
7 XBRL SCHEMA FILE ddrt-20170331.xsd EX-101.SCH 48882
8 XBRL CALCULATION FILE ddrt-20170331_cal.xml EX-101.CAL 50052
9 XBRL DEFINITION FILE ddrt-20170331_def.xml EX-101.DEF 163273
10 XBRL LABEL FILE ddrt-20170331_lab.xml EX-101.LAB 427206
11 XBRL PRESENTATION FILE ddrt-20170331_pre.xml EX-101.PRE 303937
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

IRS No.: 452259340 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54478 | Film No.: 17844305
SIC: 2834 Pharmaceutical Preparations